Whether you can delay cancer treatment by two weeks depends entirely on your specific diagnosis, cancer stage, and treatment goals. You should never delay cancer treatment without consulting your oncologist. While minor delays are sometimes medically necessary or planned, delaying treatment can risk tumor growth and decrease overall survival odds. 

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “For most solid tumours, two weeks spent planning properly serves a patient far better than two weeks saved by rushing, but I’d never apply that to an aggressive blood cancer, where the calendar genuinely matters.”

Most cancers just don’t move that fast. And a short wait, used well, tends to help.

• Scans aren’t done yet: One missing test can flip the whole plan. Better to see the full picture than guess at half of it.
• You want a second look: Getting another expert to check the diagnosis costs little and, more often than people expect, it shifts the plan.
• Surgery takes setting up: The right surgeon, the right slot, the right method. That doesn’t fall into place in a day, and the prep really does show later.
• Get the body ready: Sort out an infection, high sugar or a heart worry first, and there’s far less chance of things going wrong once treatment starts.

So waiting on purpose isn’t waiting for nothing. Anyone heading toward robotic cancer surgery often gets a better, safer plan out of those two weeks.

Some cancers don’t leave that room. With these, the clock is real.

• Blood cancers: Acute leukaemia and high-grade lymphomas can shift in days, so doctors usually start almost straight away.
• Symptoms getting worse fast: Pain, bleeding, trouble breathing or a blockage that’s building by the day needs acting on, not watching.
• Already spread a lot: When a tumour is big or moving quickly, even two weeks can take options off the table.
• Something under pressure: A tumour pushing on the windpipe, spine or bowel is urgent on its own, whatever the cancer normally does.

So it’s how the cancer behaves that sets the timing, not the date on the calendar. Knowing what cancer surgery hinges on makes it clear why some cases can sit tight and others really can’t.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every treatment decision across all cancer types. He tells patients plainly whether their cancer can wait or can’t, rather than defaulting to urgency or false reassurance.

That honesty is what lets patients plan without panic. Every case at MACS Clinic goes through a full tumour board, where pathology, imaging and oncology weigh in together before any timeline is set. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Cancer Treatment. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

The first week isn’t for treatment. It’s for getting your footing. The priorities are clear: confirm the diagnosis is solid, gather every report and scan in one place, and get in front of a specialist who treats your specific cancer. Most cancers allow that window, and using it well shapes every decision that follows.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The first week should be spent confirming the diagnosis and understanding the options, not panicking into a treatment that hasn’t been properly planned, because a rushed start rarely improves anything.”

Nobody hands you a checklist with the diagnosis. So here’s where the energy should go first.

• Gather records: Pull your biopsy, imaging and blood reports into one file. Every specialist you see will want them to weigh in properly.
• Find the right specialist: A doctor who treats your exact cancer at volume reads the case differently. That gap shows up in the plan you’re offered.
• Hold off on panic: It feels like an emergency, yet rushing into surgery within days rarely helps and can lock you into the wrong path.
• Bring someone along: A second set of ears catches what you’ll miss. Nobody absorbs much in the appointment right after hearing the news.

None of this slows treatment down. It’s groundwork, and patients heading toward robotic cancer surgery start from a far stronger position when the first week is handled well.

Early, ideally within this first week, and for solid reasons. Here’s why it’s worth doing now.

• Confirms the diagnosis: Another specialist checking the pathology and staging can catch the rare error before it shapes your entire treatment.
• Opens up options: A fresh set of eyes sometimes surfaces approaches the first consultation never raised, which matters when treatments carry lasting consequences.
• Before treatment starts: Once chemo or surgery is underway, your choices narrow fast, so the time to look around is now, not later.
• Settles the fear: Even when the second view agrees, knowing the plan has been tested takes a lot of weight off those early days.

So it isn’t a sign of distrust. The same thinking behind a second opinion at any stage applies here, get the diagnosis right before committing to anything.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the care of newly diagnosed patients across all cancer types. He sees patients personally in those first overwhelming days and explains plainly what the diagnosis means and what the realistic options are.

That early clarity is what turns panic into a plan. Every case at MACS Clinic goes through a full tumour board, where imaging, pathology and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Newly Diagnosed With Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

A suspicious biopsy report sits in the grey zone between clearly benign and confirmed cancer. It means the pathologist saw cells that look abnormal, enough to raise a flag, but not enough to call it cancer with certainty. So it isn’t a diagnosis. It’s a signal that more is needed, usually further testing or a repeat sample, before anyone can say for sure either way.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “A suspicious report isn’t bad news or good news yet, it’s a call to investigate properly, and I’d far rather act on a careful follow-up than treat or dismiss something on a guess.”

A few different things land a report in that uncertain middle. Here’s what’s usually behind it.

• Too few cells: When the sample is sparse or poorly preserved, the pathologist can see something’s off but doesn’t have enough to commit to a verdict.
• Borderline appearance: Some cells sit right between normal and malignant, showing early changes that could go either way without more information.
• Overlapping features: Certain benign conditions mimic cancer closely under the microscope, and telling them apart often needs more than a first look.
• Sampling spot: If the needle caught the edge rather than the core of a lump, the most telling cells may simply not be in the sample.

So “suspicious” often says more about the sample than the disease. Anyone heading toward robotic cancer surgery needs that uncertainty resolved first, not carried into the operating room.

The report isn’t the finish line, it’s a prompt for the next step. This is what usually follows.

• Special staining: Pathologists apply molecular tests that tag specific proteins, turning a borderline read into a much clearer answer about the cell type.
• Repeat biopsy: Sometimes the simplest fix is a fresh sample, ideally a core biopsy that pulls more tissue than the first attempt managed.
• Expert review: A second pathologist, often a specialist in that cancer type, can settle a difficult case that one reading left open.
• Clinical correlation: The result gets weighed against your scans and symptoms, because a report never stands entirely on its own.

So uncertainty is temporary, not permanent. Much like what an IHC test adds to the picture, the next test is what turns “suspicious” into something you can actually act on.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery. He’s spent much of that time in exactly these diagnostic grey zones, where a report and a clinical picture don’t quite line up and someone has to decide the next move.

And that judgment is what keeps a suspicious report from becoming either overtreatment or a missed cancer. Every case at MACS Clinic runs through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. 1. 1. National Cancer Institute — Pathology Reports. https://www.cancer.gov/
      2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

FNAC is surprisingly accurate for what it is, a thin needle drawing a few cells from a lump. In experienced hands it gets the answer right well over ninety percent of the time for many cancers, especially in the thyroid, breast and lymph nodes. It isn’t flawless though, and when the result is unclear or the sample’s too thin, a core biopsy usually takes over to settle it.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I trust FNAC for a thyroid or lymph node lump, but I never let a single negative result overrule a lump that looks and feels like cancer, that’s when I push straight to a core biopsy.”

Accuracy isn’t fixed. It swings a lot depending on a few things going right.

• Who does it: A skilled hand placing the needle in the right spot changes everything, since a sample drawn from the edge of a lump can miss the cancer entirely.
• Cell quality: The pathologist needs enough clear cells to judge, and a sparse or bloody sample is where false negatives tend to creep in.
• Cancer type: Some tumours shed cells that read easily, while others, like certain follicular thyroid cancers, simply can’t be confirmed by cells alone.
• The lump itself: Tiny, deep or hard-to-reach lumps are harder to sample cleanly, which is exactly when accuracy starts to dip.

So a “negative” FNAC isn’t always the end of it. Anyone weighing up robotic cancer surgery wants that diagnosis nailed down first, not left on a borderline result.

Sometimes cells alone don’t cut it. Here’s when your doctor reaches for the next test.

• Unclear result: If the FNAC comes back inconclusive or suspicious rather than definite, a core biopsy gives the tissue needed to be sure.
• Architecture matters: FNAC shows cells, not how they’re arranged, and for some cancers that arrangement is what confirms the type.
• Planning treatment: Detailed tests like hormone receptors or molecular markers often need a tissue sample, which FNAC can’t always provide.
• Result and clinic clash: When a clean FNAC sits next to a worrying lump or scan, that mismatch is a clear signal to dig deeper.

So FNAC and tissue testing aren’t rivals, they work in sequence. Much like the choice explained in our core biopsy comparison, it’s about matching the test to what the case actually needs.

Dr. Sandeep Nayak has spent 24 years in surgical oncology, with DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery. He reads an FNAC report the way a surgeon has to, never in isolation, always against the lump, the scans and the bigger clinical picture.

And that’s what stops a borderline result from becoming a wrong turn. Every case at MACS Clinic runs through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Fine Needle Aspiration. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

A doctor orders a PET scan after a CT because the two tests answer different questions. A CT shows the size, shape and location of a mass, while a PET reveals how metabolically active that tissue actually is. Cancer cells burn glucose fast, so they light up on a PET in a way a CT simply can’t show. Together they confirm whether the disease is active and how far it has spread.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “A CT tells me what a lump looks like, but a PET tells me whether it’s behaving like cancer, and that difference often decides the whole treatment plan.”

A CT maps anatomy. A PET maps activity. That gap is the entire reason both get used.

• Cell activity: PET picks up the high glucose uptake of cancer cells, so it flags disease that’s biologically active rather than just a shadow on an image.
• Hidden spread: Small deposits in lymph nodes or distant organs often stay invisible on CT, and PET catches many of them before they grow large enough to see.
• Scar vs cancer: After treatment, a CT can show a lingering mass that’s only scar tissue, and PET tells whether it’s dead or still alive.
• Whole body: One PET scan surveys the entire body at once, which matters when the worry is spread rather than a single known site.

So the two aren’t rivals. A patient working through their cancer staging gets a far more complete picture when structure and activity are read side by side.

Not every case needs one. But in specific situations a PET changes the decision entirely.

• Staging: When a cancer is confirmed, PET helps pin the true stage by checking whether it has quietly travelled beyond the primary site.
• Unclear findings: If a CT shows something borderline that could go either way, PET often settles whether it’s worth a biopsy or surgery.
• Treatment response: Midway through chemo or radiation, PET shows whether the tumour is genuinely shrinking in activity, not just in size.
• Suspected recurrence: When markers rise but a CT looks clean, PET can locate disease that’s returned before anything else picks it up.

So the timing isn’t random. Much like getting a second opinion, the extra scan is about confirming the picture before committing to a plan.

Dr. Sandeep Nayak holds a DNB in Surgical Oncology and General Surgery, with 24 years in the field and a practice built entirely around cancer. He reads imaging the way a surgeon has to, looking not just at what a scan shows but at what it means for whether, when and how to operate.

For a patient, that’s the difference between a scan report and a plan. Every case at MACS Clinic goes through a full tumour board, where imaging, pathology and oncology are weighed together before anything is confirmed. Reach the team at 📞 +91 9482202240.

References:

1. National Cancer Institute — PET Scans. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer